©2024 Stanford Medicine
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD
Not Recruiting
Trial ID: NCT00206167
Purpose
The purpose of this study is to compare Symbicort in a pressurized metered-dose inhaler
(pMDI) with formoterol and placebo in the long-term maintenance treatment of patients with
chronic obstructive pulmonary disease (COPD).
Official Title
A 12-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy and Safety Study of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid Compared to Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD
Stanford Investigator(s)
Eligibility
Inclusion Criteria:
- A clinical diagnosis of COPD with symptoms for more than 2 years.
- Smoking history of 10 or more pack years
- A history of at least one COPD exacerbation requiring a course of oral steroids and/or
antibiotics within 1-12 months before first visit.
Exclusion Criteria:
- A history of asthma
- Patients taking oral steroids
- Any significant disease or disorder that may jeopardize the safety of the patient
Intervention(s):
drug: Budesonide/formoterol pMDI
drug: Formoterol Turbuhaler
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Ware Kuschner
6504935000 x 63544